Small doses of cyclophosphamide for induction of remission and maintenance therapy for lupus nephritis efficacy

【Objective】To investigate the low-dose cyclophosphamide for induction of remission and maintain clinical efficacy of the treatment of lupus nephritis.【Methods】80 cases of systemic lupus erythematosus patients with proliferative glomerulonephritis were randomly divided into study group and the control group, 40 cases in each group. In the control group were treated with high-dose cyclophosphamide treatment, the study group were treated with lowdose cyclophosphamide treatment. The clinical efficacy of the two groups of patients and adverse reactions after 1 year of treatment.【Results】24 h proteinuria two groups of patients, ds-DNA antibodies, complement C3 and SLEDAI other indicators compared with before treatment, differences were statistically significant(all P0.05). The incidence of serious infections and study groups menstrual disorders and other adverse reactions was significantly lower than the control group, differences were statistically significant(P0.05).【Conclusion】Low-dose cyclophosphamide for induction of remission and maintenance treatment of lupus nephritis efficacy with traditional high-dose intravenous pulse cyclophosphamide considerable efficacy, and adverse reactions decreased, worthy of promotion.